Omnicell (NASDAQ:OMCL) Lowered to Hold at Zacks Investment Research

Omnicell (NASDAQ:OMCLGet Rating) was downgraded by Zacks Investment Research from a “strong-buy” rating to a “hold” rating in a research note issued to investors on Tuesday, Zacks.com reports. They currently have a $117.00 price target on the stock. Zacks Investment Research‘s price target indicates a potential upside of 7.94% from the company’s current price.

According to Zacks, “Omnicell exited the first quarter of 2022 with earnings and revenues ahead of the Zacks Consensus Estimate. The top line was driven by strong revenue contributions from the company’s operating segments. The ongoing robust demand for Omnicell’s medication management solutions buoys optimism. The revenue contributions from the latest acquisitions of FDS Amplicare, ReCept and MarkeTouch Media also instill investors’ confidence. The company’s raised adjusted earnings per share (EPS) guidance for 2022 is indicative of consistent growth momentum. In the past year, Omnicell has outperformed its industry. However, mounting operating expenses have been placing significant pressure on the company’s bottom line. The current inflationary environment as well the geopolitical scenario continues to pose challenges.”

A number of other research analysts have also issued reports on OMCL. StockNews.com began coverage on shares of Omnicell in a research note on Thursday, March 31st. They set a “hold” rating on the stock. Wells Fargo & Company lowered their target price on shares of Omnicell from $188.00 to $158.00 and set an “overweight” rating on the stock in a research report on Tuesday, May 3rd. Piper Sandler lowered their target price on shares of Omnicell from $181.00 to $162.00 in a research report on Monday, May 2nd. Finally, TheStreet lowered shares of Omnicell from a “b-” rating to a “c+” rating in a research report on Tuesday, May 17th. Three investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat.com, Omnicell has a consensus rating of “Buy” and an average price target of $168.00.

Shares of NASDAQ:OMCL traded down $2.53 on Tuesday, reaching $108.39. The company’s stock had a trading volume of 2,733 shares, compared to its average volume of 437,757. The stock’s 50-day moving average is $120.63 and its two-hundred day moving average is $146.54. Omnicell has a 52-week low of $104.32 and a 52-week high of $187.29. The stock has a market capitalization of $4.79 billion, a P/E ratio of 73.13, a PEG ratio of 2.67 and a beta of 1.20.

Omnicell (NASDAQ:OMCLGet Rating) last issued its quarterly earnings results on Thursday, April 28th. The company reported $0.53 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.40 by $0.13. Omnicell had a net margin of 6.00% and a return on equity of 11.35%. The business had revenue of $319.00 million for the quarter, compared to analyst estimates of $313.98 million. During the same period in the previous year, the business posted $0.62 earnings per share. The business’s revenue was up 26.7% compared to the same quarter last year. On average, sell-side analysts forecast that Omnicell will post 2.61 earnings per share for the current year.

A number of large investors have recently bought and sold shares of the business. Vanguard Group Inc. raised its stake in Omnicell by 0.3% during the first quarter. Vanguard Group Inc. now owns 4,752,906 shares of the company’s stock worth $615,453,000 after purchasing an additional 12,413 shares during the period. Conestoga Capital Advisors LLC raised its stake in Omnicell by 12.5% during the first quarter. Conestoga Capital Advisors LLC now owns 1,691,338 shares of the company’s stock worth $219,011,000 after purchasing an additional 188,112 shares during the period. Clearbridge Investments LLC raised its stake in Omnicell by 8.9% during the first quarter. Clearbridge Investments LLC now owns 1,136,664 shares of the company’s stock worth $147,187,000 after purchasing an additional 92,567 shares during the period. Macquarie Group Ltd. raised its stake in shares of Omnicell by 9.8% in the 3rd quarter. Macquarie Group Ltd. now owns 1,118,537 shares of the company’s stock valued at $166,025,000 after acquiring an additional 99,512 shares during the period. Finally, Dimensional Fund Advisors LP raised its stake in shares of Omnicell by 0.6% in the 1st quarter. Dimensional Fund Advisors LP now owns 848,688 shares of the company’s stock valued at $109,901,000 after acquiring an additional 4,839 shares during the period.

Omnicell Company Profile (Get Rating)

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; Omnicell Interface Software that offers interface and integration between its medication-use products or supply products, and a healthcare facility's in-house information management systems; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.

Recommended Stories

Get a free copy of the Zacks research report on Omnicell (OMCL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Omnicell (NASDAQ:OMCL)

Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.